News InflaRx stock halves after it drops lead drug InflaRx has abandoned its drug development programme, vilobelimab for rare skin disease pyoderma gangrenosum, cratering its share price.
News InflaRx flatlines after skin disease drug flops in midstage ... Shares in German biotech InflaRx have plummeted 92% after it reported a comprehensive miss for its lead drug IFX-1 in a debilitating skin disease.
Digital Axtria Ignite 2025: Madhavi Ramakrishna on leadership, cultu... GSK's Madhavi Ramakrishna was the recipient of one of the annual Axtria Ignite Leadership Awards presented at the invite-only summit.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
